SABS earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E 8.33. Updated 2026-07-23.
SAB Biotherapeutics (SABS) Research Hub
SAB Biotherapeutics (SABS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.41 USD (-2.01%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 8.33, market cap 0.03B. This hub links to the full technical, earnings and options research available for SABS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.41 USD (-2.01%) |
| 52-week range | 3.35 USD – 4.19 USD |
| Trend regime | Range |
| 14-day RSI | 19 (Oversold) |
| Trailing P/E | 8.33 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for SABS
Covered Call on SABS: how it works, illustrative setup around the real 3.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SABS: how it works, illustrative setup around the real 3.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SABS: how it works, illustrative setup around the real 3.41 USD price, max profit/loss, breakeven and when to use it. Educational.
SABS technical analysis: range, last 3.41 USD, RSI 19, 52w range 3.35 USD–4.19 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SABS in?
SAB Biotherapeutics (SABS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SABS in an uptrend or downtrend?
As of 2026-09-11, SABS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SABS's trailing P/E ratio?
SABS's trailing P/E is 8.33, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does SABS next report earnings?
SABS is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.29 USD.